Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

Sep 19, 2024 · Edgewise Therapeutics NASDAQ: EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic …

50%
OFF

Edgewise Therapeutics Soars 50%: Key Reasons Behind The Surge

2 weeks from now

Sep 19, 2024 · Edgewise Therapeutics NASDAQ: EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic …

marketbeat.com

100%
OFF

Edgewise Therapeutics Shares Surge On Positive Trial Results

2 weeks from now

Dec 16, 2024 · Plan ahead with key data on upcoming stock reports - all in 1 place See Calendar Get 100% ad-free experience Edgewise Therapeutics shares surge on positive trial results

investing.com

50%
OFF

Why Edgewise Therapeutics Stock Is Up 50% On Thursday - Yahoo …

2 weeks from now

Sep 19, 2024 · Shares of biopharma outfit Edgewise Therapeutics (NASDAQ: EWTX) soared more than 50% today, reaching a three-year high following an update on the clinical testing of …

yahoo.com

21%
OFF

Edgewise Therapeutics Shares Surge On Positive Trial Results

2 weeks from now

Dec 16, 2024 · Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) experienced a notable 21% increase in premarket trading today following the announcement of successful results …

investing.com

50%
OFF

Edgewise Therapeutics Soars 50%: Key Reasons Behind The Surge

2 weeks from now

Sep 19, 2024 · Edgewise Therapeutics (NASDAQ: EWTX) is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive …

nasdaq.com

50%
OFF

Edgewise Therapeutics Soars 50%: Key Reasons Behind The Surge

2 weeks from now

Sep 19, 2024 · The takeaway is that institutions, private equity, and venture capital own about 90% of this stock and insiders another 4.5%, showing a high conviction in their support. Short …

financialcontent.com

50%
OFF

Edgewise Therapeutics Sees 50% Stock Surge Following Positive …

2 weeks from now

Sep 20, 2024 · Edgewise Therapeutics, founded in 2017 and headquartered in Boulder, Colorado, has seen its market cap valuation increase to $1.68 billion USD. Financials: The company …

talk.bio

50%
OFF

Edgewise Therapeutics Soars 50%: Key Reasons Behind The Surge

2 weeks from now

Sep 19, 2024 · Edgewise Therapeutics EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic …

tradingview.com

18%
OFF

EWTX Stock Rises On Upbeat Data From Rare Muscular Disorder …

2 weeks from now

Dec 17, 2024 · Shares of Edgewise Therapeutics EWTX were up more than 18% on Monday after it announced positive results from the mid-stage CANYON study on its lead pipeline drug, …

yahoo.com

50%
OFF

Edgewise Shares Jump After Positive Heart Drug Data

2 weeks from now

Sep 20, 2024 · Edgewise Therapeutics has reported positive top-line results for its HCM treatment candidate, EDG-7500, boosting shares by over 50%. Phase II trials show improved heart …

thepharmaletter.com

50%
OFF

Edgewise Therapeutics: Exploring The 50% Stock Surge Dynamics

2 weeks from now

Sep 25, 2024 · Edgewise Therapeutics is witnessing a remarkable 50% surge in its stock price and an astounding 450% increase from its recent lows. This surge is largely attributed to …

investorshangout.com

30%
OFF

EWTX Stock Soars On Upbeat Efficacy Data From Cardiomyopathy …

2 weeks from now

Sep 19, 2024 · Shares of Edgewise Therapeutics (EWTX Quick Quote EWTX - Free Report) soared 30% in the pre-market trading on Thursday after it reported positive top-line data of …

zacks.com

$51.00
OFF

Edgewise Therapeutics Shares Maintain Price Target On Positive Data

2 weeks from now

Oct 30, 2024 · On Wednesday, Piper Sandler maintained its Overweight rating and $51.00 stock price target for Edgewise Therapeutics (NASDAQ:EWTX). The firm expressed continued …

investing.com

$50
OFF

Edgewise Therapeutics Price Target Raised To $50 From $44 At

2 weeks from now

Dec 16, 2024 · Leerink raised the firm’s price target on Edgewise Therapeutics (EWTX) to $50 from $44 and keeps an Outperform rating on the shares after the company announced the …

nasdaq.com

$50
OFF

Edgewise Therapeutics Price Target Raised To $50 From $45 At

2 weeks from now

Dec 17, 2024 · Evercore ISI analyst Cory Kasimov raised the firm’s price target on Edgewise Therapeutics (EWTX) to $50 from $45 and keeps an Outperform rating on the shares. After …

nasdaq.com

$0.36
OFF

Edgewise Therapeutics (EWTX) Earnings Date And Reports 2025

2 weeks from now

6 days ago · Edgewise Therapeutics released Q3 2024 earnings on November 7, 2024, reporting an EPS of -$0.36, which beat the consensus estimate of -$0.37 by $0.01. With a trailing EPS …

marketbeat.com

FAQs about Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge Coupon?

Why did Edgewise Therapeutics (ewtx) rise 50% today?

Shares of biopharma outfit Edgewise Therapeutics (NASDAQ: EWTX) soared more than 50% today, reaching a three-year high following an update on the clinical testing of its cardiac drug EDG-7500. The treatment shows promise in two related but distinct trials as a treatment for certain patients with improper bloodflow within the heart. ...

Should you buy Edgewise Therapeutics?

Nevertheless, Edgewise Therapeutics may be a pharmaceutical name worth adding to your long-term watch list. Its focus on the underserved markets of muscular dystrophy and hypertrophic cardiomyopathy could allow it to become a strong competitor (or perhaps even a market leader) on both fronts. ...

Who is Edgewise Therapeutics?

Edgewise Therapeutics develops small molecules for myopathies, with lead molecule sevasemten in phase 3 for Becker Muscular Dystrophy. Company was founded in 2017, backed by OrbiMed, with an experienc... ...

When will Edgewise start recruiting for a new cohort?

Edgewise remains on schedule to complete recruitment for a pivotal cohort of the CANYON study, called GRAND CANYON, which is expected to be achieved in the first quarter of 2025. If data from this cohort is also positive, management intends to start discussions with the FDA and EMA for seeking approval for sevasemten in the BMD indication. ...

Can Edgewise's edg-7500 treat hypertrophic cardiomyopathy?

Edgewise's EDG-7500 shows promise as a treatment for hypertrophic cardiomyopathy. This market is currently underserved, largely because many heart drugs can cause other cardiac problems. Interested investors should know that any potential commercialization is still years away. Much can change in the meantime. ...

Is EDG 7500 still profitable?

Even if an approval and commercialization of EDG-7500 is now in the cards, that's still years away. The biopharma company's still unprofitable in the meantime, and is still selling stock to fund operations. Indeed, it's not even generating revenue yet, with nothing in its developmental pipeline further along than phase 2 testing. ...